Advanced search
Publication Cover
Leukemia & Lymphoma Volume 58, 2017 - Issue 2
Submit an article Journal homepage
472
Views
14
CrossRef citations to date
0
Altmetric
Original Articles: Research

Novel phosphatidylinositol 3-kinase inhibitor BKM120 enhances the sensitivity of multiple myeloma to bortezomib and overcomes resistance

Wenjun Yua Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Yubao Chena Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Rufang Xianga Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Wenbin Xua Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Yan Wanga Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Jia Tonga Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Nan Zhanga Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, China
,
Yingli Wub Hongqiao International Institute of Medicine, Shanghai Tongren Hospital, Shanghai, China;c Faculty of Basic Medicine, Chemical Biology Division of Shanghai Universities E-Institutes, Key Laboratory of Cell Differentiation and Apoptosis of National Ministry of Education, School of Medicine, Shanghai Jiao Tong University, Shanghai, China
&
Hua Yana Department of Hematology, Rui-Jin Hospital, Shanghai Jiao-Tong University School of Medicine, Shanghai, ChinaCorrespondence[email protected]
 show all
Pages 428-437 | Received 06 Jan 2016, Accepted 10 May 2016, Published online: 20 Jul 2016

Citations (14)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (2)

Ling Wang, Jie Cao, Yan Liang & Jian Tao. (2023) STMN1 promotes cell malignancy and bortezomib resistance of multiple myeloma cell lines via PI3K/AKT signaling. Expert Opinion on Drug Safety 0:0.
Read now
Liangliang Li, Ye Chai, ChongYang Wu & Li Zhao. (2020) Chemokine receptor CXCR4: An important player affecting the molecular-targeted drugs commonly used in hematological malignancies. Expert Review of Hematology 13:12, pages 1387-1396.
Read now

Articles from other publishers (12)

Luca Heinemann, Klara Maria Möllers, Helal Mohammed Mohammed Ahmed, Lanying Wei, Kaiyan Sun, Subbaiah Chary Nimmagadda, Daria Frank, Anja Baumann, Alexandra M. Poos, Martin Dugas, Julian Varghese, Marc-Steffen Raab & Cyrus Khandanpour. (2022) Inhibiting PI3K–AKT–mTOR Signaling in Multiple Myeloma-Associated Mesenchymal Stem Cells Impedes the Proliferation of Multiple Myeloma Cells. Frontiers in Oncology 12.
Crossref
Reiko Isa, Mano Horinaka, Taku Tsukamoto, Kentaro Mizuhara, Yuto Fujibayashi, Yoko Taminishi-Katsuragawa, Haruya Okamoto, Shusuke Yasuda, Yuka Kawaji-Kanayama, Yayoi Matsumura-Kimoto, Shinsuke Mizutani, Yuji Shimura, Masafumi Taniwaki, Toshiyuki Sakai & Junya Kuroda. (2022) The Rationale for the Dual-Targeting Therapy for RSK2 and AKT in Multiple Myeloma. International Journal of Molecular Sciences 23:6, pages 2919.
Crossref
Karolina Łuczkowska, Katarzyna Ewa Sokolowska, Olga Taryma-Lesniak, Krzysztof Pastuszak, Anna Supernat, Jonas Bybjerg-Grauholm, Lise Lotte Hansen, Edyta Paczkowska, Tomasz K. Wojdacz & Bogusław Machaliński. (2021) Bortezomib induces methylation changes in neuroblastoma cells that appear to play a significant role in resistance development to this compound. Scientific Reports 11:1.
Crossref
Emine Öksüzoğlu & Gül Kozalak. (2021) Inhibition of apoptosis may lead to the development of bortezomib resistance in multiple myeloma cancer cells. Turkish Journal of Biochemistry 46:1, pages 65-71.
Crossref
Phuong Nguyen, Jayati Chakrabarti, Yuan Li, Khalid W. Kalim, Mengnan Zhang, Lin Zhang, Yi Zheng & Fukun Guo. (2019) Rational Targeting of Cdc42 Overcomes Drug Resistance of Multiple Myeloma. Frontiers in Oncology 9.
Crossref
Ting Yuan, Feng Zhang, Xiangxiang Zhou, Ying Li, Ya Zhang, Yangyang Xu & Xin Wang. (2019) Inhibition of the PI3K/AKT signaling pathway sensitizes diffuse large B‑cell lymphoma cells to treatment with proteasome inhibitors via suppression of BAG3. Oncology Letters.
Crossref
Ruth Eichner, Vanesa Fernández-Sáiz, Bianca-Sabrina Targosz & Florian Bassermann. 2019. 219 297 .
Dexin Kong & Zhe Zhang. 2019. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy. Protein Kinase Inhibitors as Sensitizing Agents for Chemotherapy 187 205 .
Yingying Wang, Linlin Wu, Haiyan Cai, Hu Lei, Chun-Min Ma, Li Yang, Hanzhang Xu, Qi Zhu, Zhujun Yao & Yingli Wu. (2018) YL064 directly inhibits STAT3 activity to induce apoptosis of multiple myeloma cells. Cell Death Discovery 4:1.
Crossref
F Zhang, D M Virshup & J K Cheong. (2017) Oncogenic RAS-induced CK1α drives nuclear FOXO proteolysis. Oncogene 37:3, pages 363-376.
Crossref
Ru-Fang Xiang, Yan Wang, Nan Zhang, Wen-Bin Xu, Yang Cao, Jia Tong, Jun-min Li, Ying-Li Wu & Hua Yan. (2017) MK2206 enhances the cytocidal effects of bufalin in multiple myeloma by inhibiting the AKT/mTOR pathway. Cell Death & Disease 8:5, pages e2776-e2776.
Crossref
Gege Chen, Zhijian Xu, Gaomei Chang, Jun Hou, Liangning Hu, Yiwen Zhang, Dandan Yu, Bo Li, Shuaikang Chang, Yongsheng Xie, Yong Zhang, Rong Wei, Huiqun Wu, Wenqin Xiao, Xi Sun, Yi Tao, Lu Gao, Bojie Dai, Jumei Shi & Weiliang Zhu. (2017) The blueberry component pterostilbene has potent anti-myeloma activity in bortezomib-resistant cells. Oncology Reports 38:1, pages 488-496.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.